[1,2,4]triazines – as potential drugs in cancer chemotherapy

[1] Abi-Jaoudeh N.: TATE Versus TACE, an open-label randomized study comparing trans arterial tirapazamine embolization versus trans arterial chemo embolization in intermediate stage hepatocellular carcinoma. https://clinicaltrials.gov/ct2/show/NCT03145558 (12.12.2019) Abi-JaoudehN. TATE Versus TACE, an open-label randomized study comparing trans arterial tirapazamine embolization versus trans arterial chemo embolization in intermediate stage hepatocellular carcinoma https://clinicaltrials.gov/ct2/show/NCT03145558 (12.12.2019) Search in Google Scholar

[2] Ali R.S., Saad H.A.: Synthesis and pharmacological studies of unprecedented fused pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b] [1,3,4]thiadiazine derivatives. Molecules, 2018; 23: 1024 AliR.S. SaadH.A. Synthesis and pharmacological studies of unprecedented fused pyridazino[3′,4′:5,6][1,2,4]triazino[3,4-b] [1,3,4]thiadiazine derivatives Molecules 2018 23 1024 10.3390/molecules23051024 Search in Google Scholar

[3] Al-Temimay I.A., Al-Jibouri M.H., Hassan A.A., Mohammad F.I.: Test the cytotoxicity of pleurotin extracted from and edible mushroom Pleurotus osteratus against three human carcinoma cell line. Iraqi J. Sci., 2015; 56: 2773–2781 Al-TemimayI.A. Al-JibouriM.H. HassanA.A. MohammadF.I. Test the cytotoxicity of pleurotin extracted from and edible mushroom Pleurotus osteratus against three human carcinoma cell line Iraqi J. Sci. 2015 56 2773 2781 Search in Google Scholar

[4] Anjomshoa M., Fatemi S.J., Torkzadeh-Mahani M., Hadadzadeh H.: DNA- and BSA-binding studies and anticancer activity against human breast cancer cells (MCF-7) of the zinc(II) complex coordinated by 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine, Spectrochim. Acta A Mol. Biomol. Spectrosc., 2014; 127: 511–520 AnjomshoaM. FatemiS.J. Torkzadeh-MahaniM. HadadzadehH. DNA- and BSA-binding studies and anticancer activity against human breast cancer cells (MCF-7) of the zinc(II) complex coordinated by 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine, Spectrochim Acta A Mol. Biomol. Spectrosc. 2014 127 511 520 10.1016/j.saa.2014.02.048 Search in Google Scholar

[5] Anjomshoa M., Hadadzadeh H., Fatemi S.J., Torkzadeh-Mahani M.: A mononuclear Ni(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: DNA- and BSA-binding and anticancer activity against human breast carcinoma cells. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2015; 136: 205–215 AnjomshoaM. HadadzadehH. FatemiS.J. Torkzadeh-MahaniM. A mononuclear Ni(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: DNA- and BSA-binding and anticancer activity against human breast carcinoma cells Spectrochim. Acta A Mol. Biomol. Spectrosc. 2015 136 205 215 10.1016/j.saa.2014.09.016 Search in Google Scholar

[6] Anjomshoa M., Hadadzadeh H., Torkzadeh-Mahani M., Fatemi S.J., Adeli-Sardou M., Rudbari H.A., Nardo V.M.: A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines. Eur. J. Med. Chem., 2015; 96: 66–82 AnjomshoaM. HadadzadehH. Torkzadeh-MahaniM. FatemiS.J. Adeli-SardouM. RudbariH.A. NardoV.M. A mononuclear Cu(II) complex with 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine: Synthesis, crystal structure, DNA- and BSA-binding, molecular modeling, and anticancer activity against MCF-7, A-549, and HT-29 cell lines Eur. J. Med. Chem. 2015 96 66 82 10.1016/j.ejmech.2015.04.020 Search in Google Scholar

[7] Arpino G., Wiechmann L., Osborne C.K., Schiff R.: Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev., 2008; 29: 217–233 ArpinoG. WiechmannL. OsborneC.K. SchiffR. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance Endocr. Rev. 2008 29 217 233 10.1210/er.2006-0045 Search in Google Scholar

[8] Ashour H.M., El-Wakil M.H., Khalil M.A., Ismail K.A., Labouta I.M.: Synthesis of some (E)-6-[2-(furan-2-yl)ethenyl]-1,2,4-triazin-5-ones and their biological evaluation as antitumor agents. Med. Chem. Res., 2013; 22: 1909–1924 AshourH.M. El-WakilM.H. KhalilM.A. IsmailK.A. LaboutaI.M. Synthesis of some (E)-6-[2-(furan-2-yl)ethenyl]-1,2,4-triazin-5-ones and their biological evaluation as antitumor agents Med. Chem. Res. 2013 22 1909 1924 10.1007/s00044-012-0192-x Search in Google Scholar

[9] Branowska D., Ławecka J., Sobiczewski M., Karczmarzyk Z., Wysocki W., Wolińska E., Olender E., Mirosław B., Perzyna A., Bielawska A., Bielawski K.: Synthesis of unsymmetrical disulfanes bearing 1,2,4-triazine scaffold and their in vitro screening towards anti-breast cancer activity. Monatsh Chem., 2018; 149: 1409–1420 BranowskaD. ŁaweckaJ. SobiczewskiM. KarczmarzykZ. WysockiW. WolińskaE. OlenderE. MirosławB. PerzynaA. BielawskaA. BielawskiK. Synthesis of unsymmetrical disulfanes bearing 1,2,4-triazine scaffold and their in vitro screening towards anti-breast cancer activity Monatsh Chem. 2018 149 1409 1420 10.1007/s00706-018-2206-y Search in Google Scholar

[10] Bray F., Jemal A., Grey N., Ferlay J., Forman D.: Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol., 2012; 13: 790–801 BrayF. JemalA. GreyN. FerlayJ. FormanD. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study Lancet Oncol. 2012 13 790 801 10.1016/S1470-2045(12)70211-5 Search in Google Scholar

[11] Cascioferro S., Parrino B., Spanò V., Carbone A., Montalbano A., Barraja P., Diana P., Cirrincione G.: Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives. Eur. J. Med. Chem., 2017; 142: 74–86 CascioferroS. ParrinoB. SpanòV. CarboneA. MontalbanoA. BarrajaP. DianaP. CirrincioneG. Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives Eur. J. Med. Chem. 2017 142 74 86 10.1016/j.ejmech.2017.06.00328615111 Search in Google Scholar

[12] Cortez D., Reuther G., Pendergast A.M.: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene, 1997; 15: 2333–2342 CortezD. ReutherG. PendergastA.M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells Oncogene 1997 15 2333 2342 10.1038/sj.onc.12014009393877 Search in Google Scholar

[13] Dinh Ngoc T., Moons N., Kim Y., De Borggraeve W., Mashentseva A., Andrei G., Snoeck R., Balzarini J., Dehaen W.: Synthesis of triterpenoid triazine derivatives from allobetulone and betulonic acid with biological activities. Bioorg. Med. Chem., 2014; 22: 3392–3300 Dinh NgocT. MoonsN. KimY. De BorggraeveW. MashentsevaA. AndreiG. SnoeckR. BalzariniJ. DehaenW. Synthesis of triterpenoid triazine derivatives from allobetulone and betulonic acid with biological activities Bioorg. Med. Chem. 2014 22 3392 3300 10.1016/j.bmc.2014.04.06124844757 Search in Google Scholar

[14] Dziadziuszko R., Zyśk R.: Rak płuca – korzyści kliniczne leczenia inhibitorami ALK w świetle ograniczeń ekonomicznych w Polsce. Onkol. Prakt. Klin. Edu., 2015; 1: 54–64 DziadziuszkoR. ZyśkR. Rak płuca – korzyści kliniczne leczenia inhibitorami ALK w świetle ograniczeń ekonomicznych w Polsce Onkol. Prakt. Klin. Edu. 2015 1 54 64 Search in Google Scholar

[15] El-All A.S., Hassan A.S., Osman S.A., Yosef H.A., Abdel-Hady W.H., El-Hashash M.A., Atta-Allah S.R., Ali M.M., El Rashedy A.A.: Synthesis, characterization and biological evaluation of new fused triazine derivatives based on 6-methyl-3-thioxo-1,2,4-triazin-5-one. Acta Pol. Pharm, 2016; 73: 79–92 El-AllA.S. HassanA.S. OsmanS.A. YosefH.A. Abdel-HadyW.H. El-HashashM.A. Atta-AllahS.R. AliM.M. El RashedyA.A. Synthesis, characterization and biological evaluation of new fused triazine derivatives based on 6-methyl-3-thioxo-1,2,4-triazin-5-one Acta Pol. Pharm 2016 73 79 92 Search in Google Scholar

[16] El-All A.S., Osman S.A., Roaiah H.M., Abdalla M.M., El Aty A.A., Abd El-Hady W.H.: Potent anticancer and antimicrobial activities of pyrazole, oxazole and pyridine derivatives containing 1,2,4-triazine moiety. Med. Chem. Res., 2015; 24: 4093–4104 El-AllA.S. OsmanS.A. RoaiahH.M. AbdallaM.M. El AtyA.A. Abd El-HadyW.H. Potent anticancer and antimicrobial activities of pyrazole, oxazole and pyridine derivatives containing 1,2,4-triazine moiety Med. Chem. Res. 2015 24 4093 4104 10.1007/s00044-015-1460-3 Search in Google Scholar

[17] Ell-Wakil M.H., Ashour H.M., Saudi M.N., Hassan A.M., Labouta I.M.: Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity. Bioorg. Chem., 2018; 76: 154–165 Ell-WakilM.H. AshourH.M. SaudiM.N. HassanA.M. LaboutaI.M. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity Bioorg. Chem. 2018 76 154 165 10.1016/j.bioorg.2017.11.00629175587 Search in Google Scholar

[18] Elsayed E.H., Radwan E.M.: New potential antitumor nitrogen heterocycles: Synthesis and cytotoxic evaluation. Der Pharma Chemica, 2016; 8: 399–413 ElsayedE.H. RadwanE.M. New potential antitumor nitrogen heterocycles: Synthesis and cytotoxic evaluation Der Pharma Chemica 2016 8 399 413 Search in Google Scholar

[19] Fink B.E., Norris D., Mastalerz H., Chen P., Goyal B., Zhao Y., Kim S.H., Vite G.D., Lee F.Y., Zhang H., Oppenheimer S., Tokarski J.S., Wong T.W., Gavai A.V.: Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg. Med. Chem. Lett., 2011; 21: 781–785 FinkB.E. NorrisD. MastalerzH. ChenP. GoyalB. ZhaoY. KimS.H. ViteG.D. LeeF.Y. ZhangH. OppenheimerS. TokarskiJ.S. WongT.W. GavaiA.V. Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases Bioorg. Med. Chem. Lett. 2011 21 781 785 10.1016/j.bmcl.2010.11.10021177105 Search in Google Scholar

[20] Gao L.Z., Li T., Yu S.X., Huang W.L., Zhao H., Hu G.Q.: Design, synthesis, antibacterial and anti-cell proliferation activities of [1,2,4]triazino[3,4-h][1,8]naphthyridine-8-one-7-carboxylic acid derivatives. Acta Pharm. Sin., 2015; 50: 332–336 GaoL.Z. LiT. YuS.X. HuangW.L. ZhaoH. HuG.Q. Design, synthesis, antibacterial and anti-cell proliferation activities of [1,2,4]triazino[3,4-h][1,8]naphthyridine-8-one-7-carboxylic acid derivatives Acta Pharm. Sin. 2015 50 332 336 Search in Google Scholar

[21] Garajová I., Giovannetti E., Biasco G., Peters G.J.: c-Met as a target for personalized therapy. Transl. Oncogenomics, 2015; 7: 13–31 GarajováI. GiovannettiE. BiascoG. PetersG.J. c-Met as a target for personalized therapy Transl. Oncogenomics 2015 7 13 31 Search in Google Scholar

[22] Gavai A.V., Fink B.E., Fairfax D.J., Martin G.S., Rossiter L.M., Holst C.L., Kim S.H., Leavitt K.J., Mastalerz H., Han W.C., Norris D., Goyal B., Swaminathan S., Patel B., Mathur A. i wsp.: Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases. J. Med. Chem., 2009; 52: 6527–6530 GavaiA.V. FinkB.E. FairfaxD.J. MartinG.S. RossiterL.M. HolstC.L. KimS.H. LeavittK.J. MastalerzH. HanW.C. NorrisD. GoyalB. SwaminathanS. PatelB. MathurA. Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinases J. Med. Chem. 2009 52 6527 6530 10.1021/jm901006519821562 Search in Google Scholar

[23] Gazieva G.A., Izmest’ev A.N., Anikina L.V., Pukhov S.A., Meshchaneva M.E., Khakimov D.V., Kolotyrkina N.G., Kravchenko A.N.: The influence of substituents on reactivity and cytotoxicity of imidazothiazolotriazinones. Mol. Divers., 2018; 22: 585–599 GazievaG.A. Izmest’evA.N. AnikinaL.V. PukhovS.A. MeshchanevaM.E. KhakimovD.V. KolotyrkinaN.G. KravchenkoA.N. The influence of substituents on reactivity and cytotoxicity of imidazothiazolotriazinones Mol. Divers. 2018 22 585 599 10.1007/s11030-018-9813-829542013 Search in Google Scholar

[24] Gucký T., Fryšová I., Slouka J., Hajdúch M., Džubák P.: Cyclo-condensation reaction of heterocyclic carbonyl compounds, Part XIII: Synthesis and cytotoxic activity of some 3,7-diaryl-5-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e][1,2,4]triazines. Eur. J. Med. Chem., 2009; 44: 891–900 GuckýT. FryšováI. SloukaJ. HajdúchM. DžubákP. Cyclo-condensation reaction of heterocyclic carbonyl compounds, Part XIII: Synthesis and cytotoxic activity of some 3,7-diaryl-5-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e][1,2,4]triazines Eur. J. Med. Chem. 2009 44 891 900 10.1016/j.ejmech.2008.05.02618632190 Search in Google Scholar

[25] Gucký T., Řezníčková E., Džubák P., Hajdúch M., Kryštof V.: Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines. Monatsh Chem., 2010; 141: 709–714 GuckýT. ŘezníčkováE. DžubákP. HajdúchM. KryštofV. Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines Monatsh Chem. 2010 141 709 714 10.1007/s00706-010-0314-4 Search in Google Scholar

[26] Gumulec J., Balvan J., Sztalmachova M., Raudenska M., Dvorakova V., Knopfova L., Polanska H., Hudcova K., Ruttkay-Nedecky B., Babula P., Adam V., Kizek R., Stiborova M., Masarik M.: Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int. J. Oncol., 2014; 44: 923–933 GumulecJ. BalvanJ. SztalmachovaM. RaudenskaM. DvorakovaV. KnopfovaL. PolanskaH. HudcovaK. Ruttkay-NedeckyB. BabulaP. AdamV. KizekR. StiborovaM. MasarikM. Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle Int. J. Oncol. 2014 44 923 933 10.3892/ijo.2013.222324366574 Search in Google Scholar

[27] Juszczyński P.: Nowe cele terapii ukierunkowanej w nowotworach układu chłonnego z perspektywy ostatnich 5 lat badań. Hematologia, 2015; 6: 1–9 JuszczyńskiP. Nowe cele terapii ukierunkowanej w nowotworach układu chłonnego z perspektywy ostatnich 5 lat badań Hematologia 2015 6 1 9 10.5603/Hem.2015.0010 Search in Google Scholar

[28] Karczmarzyk Z., Wysocki W., Urbańczyk-Lipowska Z., Kalicki P., Bielawska A., Bielawski K., Ławecka J.: Synthetic approaches for sulfur derivatives containing 1,2,4-triazine moiety: Their activity for in vitro screening towards two human cancer cell lines. Chem. Pharm. Bull., 2015; 63: 531–537 KarczmarzykZ. WysockiW. Urbańczyk-LipowskaZ. KalickiP. BielawskaA. BielawskiK. ŁaweckaJ. Synthetic approaches for sulfur derivatives containing 1,2,4-triazine moiety: Their activity for in vitro screening towards two human cancer cell lines Chem. Pharm. Bull. 2015 63 531 537 10.1248/cpb.c15-0015326133068 Search in Google Scholar

[29] Keane L.A.J., Mirallai S.I., Sweeney M., Carty M.P., Zissimou G.A., Berezin A.A., Koutentis P.A., Aldabbagh F.: Anti-cancer activity of phenyl and pyrid-2-yl 1,3-substituted benzo[1,2,4]triazin-7-ones and stable free radical precursors. Molecules, 2018; 23: 574 KeaneL.A.J. MirallaiS.I. SweeneyM. CartyM.P. ZissimouG.A. BerezinA.A. KoutentisP.A. AldabbaghF. Anti-cancer activity of phenyl and pyrid-2-yl 1,3-substituted benzo[1,2,4]triazin-7-ones and stable free radical precursors Molecules 2018 23 574 10.3390/molecules23030574601794129510488 Search in Google Scholar

[30] Koziński K., Dobrzyń A.: Szlak sygnałowy Wnt i jego rola w regulacji metabolizmu komórki. Postępy Hig. Med. Dośw., 2013; 67: 1098–1108 KozińskiK. DobrzyńA. Szlak sygnałowy Wnt i jego rola w regulacji metabolizmu komórki Postępy Hig. Med. Dośw. 2013 67 1098 1108 10.5604/17322693.107771924379251 Search in Google Scholar

[31] Krzeminski P.: Receptory nukleotydowe w komórkach nowotworowych. Postępy Biochemii, 2014; 60: 490–505 KrzeminskiP. Receptory nukleotydowe w komórkach nowotworowych Postępy Biochemii 2014 60 490 505 Search in Google Scholar

[32] Kwon Y.S., Nam J.H., Kim D.Y., Suh D.S., Kim J.H., Kim Y.M., Kim Y.T.: Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy. J. Korean Med. Sci., 2009; 24: 679–683 KwonY.S. NamJ.H. KimD.Y. SuhD.S. KimJ.H. KimY.M. KimY.T. Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy J. Korean Med. Sci. 2009 24 679 683 10.3346/jkms.2009.24.4.679271920019654952 Search in Google Scholar

[33] Lee C.I., Huang C.M., Huang W.H., Lee A.R.: Synthesis, preferentially hypoxic apoptosis and anti-angiogenic activity of 3-amino-1,2,4-benzotriazine-1,4-dioxide bearing alkyl linkers with a 3-amino-1,2,4-benzotriazine-1-oxide moiety. Anticancer Agents Med. Chem., 2014; 14: 1428–1446 LeeC.I. HuangC.M. HuangW.H. LeeA.R. Synthesis, preferentially hypoxic apoptosis and anti-angiogenic activity of 3-amino-1,2,4-benzotriazine-1,4-dioxide bearing alkyl linkers with a 3-amino-1,2,4-benzotriazine-1-oxide moiety Anticancer Agents Med. Chem. 2014 14 1428 1446 10.2174/1871520614666141014130554442839225312508 Search in Google Scholar

[34] Li Q., Lescrinier E., Groaz E., Persoons L., Daelemans D., Herdewijn P., De Jonghe S.: Synthesis and biological evaluation of pyrrolo[2,1-f][1,2,4]triazine c-nucleosides with a ribose, 2′-deoxyribose, and 2′,3′-dideoxyribose sugar moiety. Chem. Med. Chem., 2018; 13: 97–104 LiQ. LescrinierE. GroazE. PersoonsL. DaelemansD. HerdewijnP. De JongheS. Synthesis and biological evaluation of pyrrolo[2,1-f][1,2,4]triazine c-nucleosides with a ribose, 2′-deoxyribose, and 2′,3′-dideoxyribose sugar moiety Chem. Med. Chem. 2018 13 97 104 10.1002/cmdc.20170065729160955 Search in Google Scholar

[35] Lou J., Zhou X., Weng Q., Wang D.D., Xia Q., Hu Y., He Q., Yang B., Lou P.: XQ2, a novel TPZ derivative induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells. Biosci. Biotechnol. Biochem., 2010; 74: 1181–1187 LouJ. ZhouX. WengQ. WangD.D. XiaQ. HuY. HeQ. YangB. LouP. XQ2, a novel TPZ derivative induced G2/M phase arrest and apoptosis under hypoxia in non-small cell lung cancer cells Biosci. Biotechnol. Biochem. 2010 74 1181 1187 10.1271/bbb.9088920530905 Search in Google Scholar

[36] Makki M.S.I., Abdel-Rahman R.M., Khan K.A.: Fluorine substituted 1,2,4-triazinones as potential anti-HIV-1 and CDK2 inhibitors. J. Chem., 2014; 2014: 430573 MakkiM.S.I. Abdel-RahmanR.M. KhanK.A. Fluorine substituted 1,2,4-triazinones as potential anti-HIV-1 and CDK2 inhibitors J. Chem. 2014 2014 430573 10.1155/2014/430573 Search in Google Scholar

[37] Mojzych M.: Cytotoxic activity of some pyrazolo[4,3-e][1,2,4] triazines against human cancer cell lines. J. Chem. Soc. Pak., 2011; 33: 123–128 MojzychM. Cytotoxic activity of some pyrazolo[4,3-e][1,2,4] triazines against human cancer cell lines J. Chem. Soc. Pak. 2011 33 123 128 Search in Google Scholar

[38] Mojzych M., Bielawska A., Bielawski K., Ceruso M., Supuran C.T.: Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity. Bioorg. Med. Chem., 2014; 22: 2643–2647 MojzychM. BielawskaA. BielawskiK. CerusoM. SupuranC.T. Pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors with antitumor activity Bioorg. Med. Chem. 2014 22 2643 2647 10.1016/j.bmc.2014.03.02924713308 Search in Google Scholar

[39] Mojzych M., Šubertová V., Bielawska A., Bielawski K., Bazgier V., Berka K., Gucký T., Fornal E., Kryštof V.: Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. Eur. J. Med. Chem., 2014; 78: 217–224 MojzychM. ŠubertováV. BielawskaA. BielawskiK. BazgierV. BerkaK. GuckýT. FornalE. KryštofV. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines Eur. J. Med. Chem. 2014 78 217 224 10.1016/j.ejmech.2014.03.05424681986 Search in Google Scholar

[40] Mojzych M., Tarasiuk P., Karczmarzyk Z., Juszczak M., Rzeski W., Fruziński A., Woźny A.: Synthesis, structure and antiproliferative activity of new pyrazolo[4,3-e]triazolo[4,5-b][1,2,4]triazine derivatives. Med Chem., 2018; 14: 53–59 MojzychM. TarasiukP. KarczmarzykZ. JuszczakM. RzeskiW. FruzińskiA. WoźnyA. Synthesis, structure and antiproliferative activity of new pyrazolo[4,3-e]triazolo[4,5-b][1,2,4]triazine derivatives Med Chem. 2018 14 53 59 10.2174/157340641366617102011492429065838 Search in Google Scholar

[41] Nassar I.F.: Synthesis and antitumor activity of new substituted mercapto-1,2,4-triazine derivatives, their thioglycosides, and acyclic thioglycoside analogs. J. Heterocyclic Chem., 2013; 50: 129–134 NassarI.F. Synthesis and antitumor activity of new substituted mercapto-1,2,4-triazine derivatives, their thioglycosides, and acyclic thioglycoside analogs J. Heterocyclic Chem. 2013 50 129 134 10.1002/jhet.1022 Search in Google Scholar

[42] Ndagi U., Mhlongo N., Soliman M.E.: Metal complexes in cancer therapy – an update from drug design perspective. Drug Des. Devel. Ther., 2017; 11: 599–616 NdagiU. MhlongoN. SolimanM.E. Metal complexes in cancer therapy – an update from drug design perspective Drug Des. Devel. Ther. 2017 11 599 616 10.2147/DDDT.S119488534441228424538 Search in Google Scholar

[43] Noriega-Guerra H., Freitas V.M.: Extracellular matrix influencing HGF/c-MET signaling pathway: Impact on cancer progression. Int. J. Mol. Sci., 2018; 19: 3300 Noriega-GuerraH. FreitasV.M. Extracellular matrix influencing HGF/c-MET signaling pathway: Impact on cancer progression Int. J. Mol. Sci. 2018 19 3300 10.3390/ijms19113300627494430352967 Search in Google Scholar

[44] Ott G.R., Wells G.J., Thieu T.V., Quail M.R., Lisko J.G., Mesaros E.F., Gingrich D.E., Ghose A.K., Wan W., Lu L., Cheng M., Albom M.S., Angeles T.S., Huang Z., Aimone L.D., Ator M.A., Ruggeri B.A., Dorsey B.D.: 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J. Med. Chem., 2011; 54: 6328–6341 OttG.R. WellsG.J. ThieuT.V. QuailM.R. LiskoJ.G. MesarosE.F. GingrichD.E. GhoseA.K. WanW. LuL. ChengM. AlbomM.S. AngelesT.S. HuangZ. AimoneL.D. AtorM.A. RuggeriB.A. DorseyB.D. 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity J. Med. Chem. 2011 54 6328 6341 10.1021/jm200758k21859094 Search in Google Scholar

[45] Pastorekova S., Gillies R.J.: The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis and beyond. Cancer Metastasis Rev., 2019; 38: 65–77 PastorekovaS. GilliesR.J. The role of carbonic anhydrase IX in cancer development: Links to hypoxia, acidosis and beyond Cancer Metastasis Rev. 2019 38 65 77 10.1007/s10555-019-09799-0664736631076951 Search in Google Scholar

[46] Powis G.: Triazine and hydrazine derivatives. W: Cancer Growth and Progression: H.E. Kaiser. Kluwer Academic Publishers, Dordrecht Netherlands, 1989, 113–118 PowisG. Triazine and hydrazine derivatives W: Cancer Growth and Progression: H.E. Kaiser Kluwer Academic Publishers Dordrecht Netherlands 1989 113 118 10.1007/978-94-009-1095-9_9 Search in Google Scholar

[47] Ranjbar S., Edraki N., Khoshneviszadeh M., Foroumadi A., Miri R., Khoshneviszadeh M.: Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors. Res. Pharm. Sci., 2018; 13: 1–11 RanjbarS. EdrakiN. KhoshneviszadehM. ForoumadiA. MiriR. KhoshneviszadehM. Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors Res. Pharm. Sci. 2018 13 1 11 10.4103/1735-5362.220962577207629387106 Search in Google Scholar

[48] Reddy S.B., Williamson S.K.: Tirapazamine: A novel agent targeting hypoxic tumor cells. Expert Opin. Investig. Drugs, 2009; 18: 77–87 ReddyS.B. WilliamsonS.K. Tirapazamine: A novel agent targeting hypoxic tumor cells Expert Opin. Investig. Drugs 2009 18 77 87 10.1517/1354378080256725019053884 Search in Google Scholar

[49] Saad H.A., Moustafa A.H.: Synthesis and anticancer activity of some new s-glycosyl and s-alkyl 1,2,4-triazinone derivatves. Molecules, 2011; 16: 5682–5700 SaadH.A. MoustafaA.H. Synthesis and anticancer activity of some new s-glycosyl and s-alkyl 1,2,4-triazinone derivatves Molecules 2011 16 5682 5700 10.3390/molecules16075682626434621727893 Search in Google Scholar

[50] Saad H.A., Youssef M.M., Mosselhi M.A.: Microwave assisted synthesis of some new fused 1,2,4-triazines bearing thiophene moieties with expected pharmacological activity. Molecules, 2011; 16: 4937–4957 SaadH.A. YoussefM.M. MosselhiM.A. Microwave assisted synthesis of some new fused 1,2,4-triazines bearing thiophene moieties with expected pharmacological activity Molecules 2011 16 4937 4957 10.3390/molecules16064937626420421677606 Search in Google Scholar

[51] Safaie Qamsari E., Safaei Ghaderi S., Zarei B., Dorostkar R., Bagheri S., Jadidi-Niaragh F., Somi M.H., Yousefi M.: The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumour Biol., 2017; 39: 1010428317699118 Safaie QamsariE. Safaei GhaderiS. ZareiB. DorostkarR. BagheriS. Jadidi-NiaraghF. SomiM.H. YousefiM. The c-Met receptor: Implication for targeted therapies in colorectal cancer Tumour Biol. 2017 39 1010428317699118 10.1177/101042831769911828459362 Search in Google Scholar

[52] Ścibor-Bentkowska D., Czeczot H.: Komórki nowotworowe a stres oksydacyjny. Postępy Hig. Med. Dośw., 2009; 63: 58–72 Ścibor-BentkowskaD. CzeczotH. Komórki nowotworowe a stres oksydacyjny Postępy Hig. Med. Dośw. 2009 63 58 72 Search in Google Scholar

[53] Seibert W.: Uber den Mechanismus der Reaktion von Kishner-Wolff-Staudinger. I. Mildeilung. Chem. Ber., 1947; 80: 494–502 SeibertW. Uber den Mechanismus der Reaktion von Kishner-Wolff-Staudinger I. Mildeilung. Chem. Ber. 1947 80 494 502 10.1002/cber.19470800604 Search in Google Scholar

[54] Shang S., Hua F., Hu Z.W.: The regulation of β-catenin activity and function in cancer: Therapeutic opportunites. Oncotarget, 2017; 8: 33972–33989 ShangS. HuaF. HuZ.W. The regulation of β-catenin activity and function in cancer: Therapeutic opportunites Oncotarget 2017 8 33972 33989 10.18632/oncotarget.15687546492728430641 Search in Google Scholar

[55] Shnider B.I., Frei E., Tuohy J.H., Gorman J., Freireich E.J., Brindley C.O.Jr., Clements J.: Clinical studies of 6-azauracil. Cancer Res., 1960; 20: 28–33 ShniderB.I. FreiE. TuohyJ.H. GormanJ. FreireichE.J. BrindleyC.O.Jr. ClementsJ. Clinical studies of 6-azauracil Cancer Res. 1960 20 28 33 Search in Google Scholar

[56] Showalter H.D., Turbiak A.J., Fearon E.R., Bommer G.T.: Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same. Patent No. US 20110166144 A1, 2011 ShowalterH.D. TurbiakA.J. FearonE.R. BommerG.T. Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same Patent No. US 20110166144 A1 2011 Search in Google Scholar

[57] Smith A.B., Thoma G., Van Eis M.: Monocyclic heteroarylcycloalkyldiamine derivatives. WO 2013171690 A1, 2013 SmithA.B. ThomaG. VanEis M. Monocyclic heteroarylcycloalkyldiamine derivatives WO 2013171690 A1 2013 Search in Google Scholar

[58] Soria J.C., Cortes J., Massard C., Armand J.P., De Andreis D., Ropert S., Lopez E., Catteau A., James J., Marier J.F., Beliveau M., Martell R.E., Baselga J.: Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann. Oncol., 2012; 23: 463–471 SoriaJ.C. CortesJ. MassardC. ArmandJ.P. De AndreisD. RopertS. LopezE. CatteauA. JamesJ. MarierJ.F. BeliveauM. MartellR.E. BaselgaJ. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors Ann. Oncol. 2012 23 463 471 10.1093/annonc/mdr13721576284 Search in Google Scholar

[59] Spoerri L., Oo Z.Y., Larsen J.E., Haass N.K., Gabrielli B., Pavey S.: Cell cycle checkpoint and DNA damage response defects as anticancer targets: From molecular mechanisms to therapeutic opportunities. W: Stress Response Pathways in Cancer: G. Wondrak, Springer, 2015; 29–49 SpoerriL. OoZ.Y. LarsenJ.E. HaassN.K. GabrielliB. PaveyS. Cell cycle checkpoint and DNA damage response defects as anticancer targets: From molecular mechanisms to therapeutic opportunities W: Stress Response Pathways in Cancer: G. Wondrak Springer 2015 29 49 10.1007/978-94-017-9421-3_3 Search in Google Scholar

[60] Stępień E., Jakubiak D.: Szlak Wnt jako potencjalny cel oddziaływania nanocząstek na komórki. W: Nanocząstki i nanomateriały, red.: J. Gromadzińska, W. Wąsowicz. Zarząd Główny Polskiego Towarzystwa Toksykologicznego, Łódź 2013, 194–204 StępieńE. JakubiakD. Szlak Wnt jako potencjalny cel oddziaływania nanocząstek na komórki W: Nanocząstki i nanomateriały red.: GromadzińskaJ. WąsowiczW. Zarząd Główny Polskiego Towarzystwa Toksykologicznego Łódź 2013 194 204 Search in Google Scholar

[61] Sweeney M., Coyle R., Kavanagh P., Berezin A.A., Lo Re D., Zissimou G.A., Koutentis P.A., Carty M.P., Aldabbagh F.: Discovery of anti-cancer activity for benzo[1,2,4]triazin-7-ones: Very strong correlation to pleurotin and thioredoxin reductase inhibition. Bioorg. Med. Chem., 2016; 24: 3565–3570 SweeneyM. CoyleR. KavanaghP. BerezinA.A. Lo ReD. ZissimouG.A. KoutentisP.A. CartyM.P. AldabbaghF. Discovery of anti-cancer activity for benzo[1,2,4]triazin-7-ones: Very strong correlation to pleurotin and thioredoxin reductase inhibition Bioorg. Med. Chem. 2016 24 3565 3570 10.1016/j.bmc.2016.05.06627290691 Search in Google Scholar

[62] Sztanke K., Pasternak K., Sztanke M., Kandefer-Szerszeń M., Kozioł A.E., Dybała I.: Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones. Bioorg. Med. Chem. Lett., 2009; 19: 5095–5100 SztankeK. PasternakK. SztankeM. Kandefer-SzerszeńM. KoziołA.E. DybałaI. Crystal structure, antitumour and antimetastatic activities of disubstituted fused 1,2,4-triazinones Bioorg. Med. Chem. Lett. 2009 19 5095 5100 10.1016/j.bmcl.2009.07.03619631534 Search in Google Scholar

[63] Tadesse S., Caldon E.C., Tilley W., Wang S.: Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update. J. Med. Chem., 2019; 62: 4233–4251 TadesseS. CaldonE.C. TilleyW. WangS. Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update J. Med. Chem. 2019 62 4233 4251 10.1021/acs.jmedchem.8b0146930543440 Search in Google Scholar

[64] Voskoboynik O.Y., Kovalenko S.I., Shishkina S.V.: Benzo[e] [1,2,4]triazino[2,3-c][1,2,3]triazin-2-ones electro-deficient heterocyclic compounds with promising anticancer activity. Heterocycl. Commun., 2016; 22: 137–141 VoskoboynikO.Y. KovalenkoS.I. ShishkinaS.V. Benzo[e] [1,2,4]triazino[2,3-c][1,2,3]triazin-2-ones electro-deficient heterocyclic compounds with promising anticancer activity Heterocycl. Commun. 2016 22 137 141 10.1515/hc-2015-0190 Search in Google Scholar

[65] Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R., Balimane P., Chang C., Chen C., Discenza L., Frennesson D., Gottardis M.M., Greer A., Hurlburt W., Johnson W. i wsp.: Discover of 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J. Med. Chem., 2009; 52: 7360–7363 WittmanM.D. CarboniJ.M. YangZ. LeeF.Y. AntmanM. AttarR. BalimaneP. ChangC. ChenC. DiscenzaL. FrennessonD. GottardisM.M. GreerA. HurlburtW. JohnsonW. Discover of 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development J. Med. Chem. 2009 52 7360 7363 10.1021/jm900786r Search in Google Scholar

[66] Xin M., Zhang L., Tang F., Tu C., Wen J., Zhao X., Liu Z., Cheng L., Shen H.: Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4] triazine derivatives as novel hedgehog signaling pathway inhibitors. Bioorg. Med. Chem., 2014; 22: 1429–1440 XinM. ZhangL. TangF. TuC. WenJ. ZhaoX. LiuZ. ChengL. ShenH. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4] triazine derivatives as novel hedgehog signaling pathway inhibitors Bioorg. Med. Chem. 2014 22 1429 1440 10.1016/j.bmc.2013.12.055 Search in Google Scholar

[67] Yang S.J., Liu M.C., Zhao Q., Hu D.Y., Xue W., Yang S.: Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents. Eur. J. Med. Chem., 2015; 96: 58–65 YangS.J. LiuM.C. ZhaoQ. HuD.Y. XueW. YangS. Synthesis and biological evaluation of betulonic acid derivatives as antitumor agents Eur. J. Med. Chem. 2015 96 58 65 10.1016/j.ejmech.2015.04.006 Search in Google Scholar

[68] Yurttaş L., Demirayak Ş., Ilgın S., Atlı Ö.: In vitro antitumor activity evaluation of some 1,2,4-triazine derivatives bearing piperazine amide moiety against breast cancer cells. Bioorg. Med. Chem., 2014; 22: 6313–6323 YurttaşL. DemirayakŞ. IlgınS. AtlıÖ. In vitro antitumor activity evaluation of some 1,2,4-triazine derivatives bearing piperazine amide moiety against breast cancer cells Bioorg. Med. Chem. 2014 22 6313 6323 10.1016/j.bmc.2014.10.002 Search in Google Scholar

[69] Zeman E.M., Brown J.M., Lemmon M.J., Hirst V.K., Lee W.W.: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 1986; 12: 1239–1242 ZemanE.M. BrownJ.M. LemmonM.J. HirstV.K. LeeW.W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells Int. J. Radiat. Oncol. Biol. Phys. 1986 12 1239 1242 10.1016/0360-3016(86)90267-1 Search in Google Scholar